Clinical Trials Directory

Trials / Completed

CompletedNCT02816099

Influence of Glycaemic Balance on the Ability of Apolipoprotein C1 to Inhibit Cholesteryl Ester Transfer Protein in Type-1 Diabetes Patients

Study of the Influence of Glycaemic Balance on the Ability of Apolipoprotein C1 to Inhibit Cholesterol Ester Transfer Protein (CETP) in Type-1 Diabetes Patients

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
206 (actual)
Sponsor
Centre Hospitalier Universitaire Dijon · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Accepted

Summary

In type-1 diabetes patients, bad cholesterol tends to accumulate because apoC1 function is slowed down. ApoC1 is a protein whose role is to diminish the activity of CETP, another protein that regulates cholesterol transfer in the body. The aim of this study is to determine whether it is possible to correct apoC1 function by improving glycaemic balance. 240 persons will be recruited in this study and allocated to one of two groups: * 160 Type-1 diabetes patients with uncontrolled diabetes: * 4 additional blood samples will be taken at the time of the systematic biological examination at inclusion and then again 3 months later. * 80 control subjects with normal lipids and normal glycaemia balance will be included in the study following the results of the biological assays. * 4 blood samples will be taken at the time of inclusion.

Conditions

Interventions

TypeNameDescription
BIOLOGICALPrise de sang

Timeline

Start date
2014-11-20
Primary completion
2022-11-14
Completion
2022-11-14
First posted
2016-06-28
Last updated
2026-02-06

Locations

2 sites across 1 country: France

Source: ClinicalTrials.gov record NCT02816099. Inclusion in this directory is not an endorsement.